Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brookfield Renewable Partners

Markel

Inflation shouldn't deflate these stocks.

3 Inflation-Resistant Stocks You Can Buy Right Now

Pfizer

With stock markets down right now, shares of some value stocks can be bargains. In a shaky economy, stocks of companies that make products that are necessities can be smart choices for value investors.

AbbVie vs. Pfizer: Which Drug Stock Offers Greater Value?

British American Tobacco

Caterpillar

Cigna

DuPont de Nemours

General Motors

With investors seeking viable ideas during this strange time, overlooked blue-chip stocks to buy could offer stable contrarian upside. The post 7 Overlooked Blue-Chip Stocks to Add to Your Buy List appeared first on InvestorPlace.

7 Overlooked Blue-Chip Stocks to Add to Your Buy List

Federal Realty Investment Trust

Kimberly-Clark

Leggett & Platt

Altria

Universal Corp

Every time a bullish market commentator says things are fine, you can almost count on the market going into a tailspin.

The 7 Highest-Yielding Dividend Kings to Buy Now and Hold Forever

Abbott Labs

Allstate

Cisco Systems

Investors looking for stocks that could potentially outperform are encouraged to consider the GF Score at the top of each summary page.

4 Undervalued Names With Very High GF Scores

Gilead Sciences

GlaxoSmithKline

You'll either need a decent chunk of change or some patience.

How to Earn $10,000 a Year in Passive Retirement Income

Johnson & Johnson

All three of these companies have strong underlying businesses and offer attractive dividends.

3 Unstoppable Dividend Stocks to Buy and Never Sell

Digital Realty Trust

These dividend-paying stocks have reliable cash flows, but they've been beaten down to some very attractive prices.

2 Surefire Dividend Stocks I'd Buy Now and Hold for at Least a Decade

AbbVie Stock: Bull vs. Bear

NORTH CHICAGO, Ill. , July 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2022 financial results on Friday, July 29, 2022, before the market opens.

AbbVie to Host Second-Quarter 2022 Earnings Conference Call

Vertex Pharmaceuticals

There's plenty of growth ahead for these companies.

Want to Beat the Bear Market? Try These 2 Stocks

AbbVie stock (NYSE: ABBV) has seen a 14% rise YTD, marking a significant outperformance compared to some of its peers and the broader markets, with Johnson & Johnson stock rising 4%, Pfizer stock down 9%, and the S&P 500 index falling 20.

What's Driving AbbVie Stock Higher?

AbbVie shares have been on a long bull run but experienced a slight wobble after Q1'22 earnings were announced. That is to do with the imminent patent expiry of its $20bn per annum selling drug Humira and doubts about replacements Skyrizi and Rinvoq's earning potential.

AbbVie: Investors Don't Have Too Much To Fear Ahead Of Q2 Earnings

Drugmaker AbbVie Inc generates most of its sales in the United States, while shifting most of its profits overseas in order to avoid U.S. taxes, an interim report from the Senate Finance Committee said on Thursday.

Senate Finance report says AbbVie shifted profit overseas to cut taxes

ABBV stock is one of the best choices you can make for 2022. Even though the company is losing its Humira patent soon, it isn't slowing down.

Best Stocks for 2022: AbbVie Is a Recession-Resistant Dividend King

American Tower

AutoZone

Intuitive Surgical

Palo Alto Networks

Long-term investors can emerge stronger from inevitable economic slowdowns with savvy picks.

These 5 Top Stocks Are Set to Outperform in a Recession

Aflac

Cardinal Health

Essex Property Trust

General Dynamics

Walmart

Exxon Mobil

The second-quarter gross domestic product (GDP) is likely to end up being negative, as the latest data from the Atlanta Fed's GDPNow tracker predicts real GDP growth of −1.0% as of June 30, down from +0.3% on June 27.

We Are in a Recession: 7 Dividend Aristocrats Are the Best Second-Half Ideas

Rinvoq could be approved to treat patients in the European Union with ulcerative colitis.

This Blockbuster Drug from AbbVie Is Closer to Another Major Indication

Colgate-Palmolive

Kinder Morgan

Coca-Cola

Lowe's

NRG Energy

Dividend stocks are only becoming more attractive as income becomes increasingly paramount. These seven equities pair dividends with safety.

7 Dividend Stocks to Buy in July 2022

Bristol-Myers

3 Stocks You Can Buy and Hold for Decades

Chevron

Great dividends and great stock performances. What more could you ask for?

The 3 Best Dividend Aristocrat Stocks in the First Half of 2022: Are They Buys Now?

Even with the current bear market, the S&P 500 index's current yield is too anemic to provide lifestyle stability for most income investors. AbbVie's 3.7% dividend yield is more than double that of the broader market.

AbbVie: Buy This Dividend King For A Growing Stream Of Income

Reliable cash flows and decades-long track records make these stocks screaming buys right now.

2 of the Safest Stocks to Buy in a Recession

Merck

Seagen

Sanofi

AstraZeneca

Novartis

Roche Holding AG

Investors who are sweating the loss of patent protection for some of Big Pharma's top-selling drugs should relax.

Investors Need Not Be Alarmed by Drug Patent Expirations

The CHMP recommends approval of AbbVie's (ABBV) Rinvoq for treating adults with active non-radiographic axial spondyloarthritis.

AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication

News for AbbVie Stock (ABBV)